Drug Profile
Research programme: cancer therapeutics - Tiziana Life Sciences
Alternative Names: Anti-cancer stem cell agent - Tiziana; Bcl3i molocules - Cardiff University/ Tiziania Life Sciences; CB1; cFLIP inhibitors; JS6; OH 14; TZLS 214; TZLS101Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Cardiff University
- Developer Cardiff University; Tiziana Life Sciences
- Class Small molecules
- Mechanism of Action Apoprotein stimulants; Bcl-X protein inhibitors; Molecular motor protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Colorectal-cancer(Late-stage disease) in United Kingdom
- 28 Nov 2018 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease) in United Kingdom
- 01 Jun 2016 Preclinical trials in Colorectal cancer (Late-stage disease) in United Kingdom (unspecified route)